Novartis Strikes Deal With Chinese Manufacturer To Make CAR-T Therapy.
September 28, 2018
Reuters (9/27, Miller) reports Novartis has inked a deal with Chinese manufacturer Cellular Biomedicine to make Kymriah (tisagenlecleucel), its $475,000 gene-modifying CAR-T cancer therapy. Chinese law requires that Novartis make the drug in China if it...